ScripIt was Groundhog Day on 2 February. That week, any pharmaceutical groundhogs would have emerged from their burrows, glanced at the shadows of tariffs, a global trade war and weak Chinese demand and sc
In Vivo2024 started with early optimism at a potential rebound in deal-making with many unpartnered life sciences assets in Phase III or later (and a lot more at earlier stages), more than $800bn available i
Medtech InsightIllumina Gets FDA Nod For Comprehensive Biomarker Test The FDA has approved a cancer biomarker test and its first two companion diagnostic indications, which manufacturer Illumina, Inc. says can exa
ScripPfizer’s Roller Coaster Day When Pfizer Inc. * reported second quarter of 2024 results, its stock price initially dipped by 3%, helping the NYSE Arca Pharmaceutical index (DRG) to go down by 2% bef